XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment
AUSTIN, Texas, June 23, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer.
XBiotech’s novel anti-cancer agent, XB2001, is being assessed in combination with ONIVYDE + 5-FU/LV chemotherapy regimens. Safety and tolerability of the regimen, as well as progression-free survival, overall survival and time-to-treatment-failure will be assessed in the study.
XB2001 blocks inflammation pathways turned on by tumors that help tumors vascularize, spread and cause collateral damage to healthy tissues. By using XB2001 to block inflammation in pancreatic cancer, investigators also hope to see a reduction in serious adverse events and reduced hospitalizations of subjects. Moreover, the anti-inflammatory effects of XB2001 may make the chemotherapy more effective and less toxic.
The study is also investigating a novel clinical endpoint that XBiotech calls the “clinical benefit response”, which involves radiological assessment of muscle mass and patient reported measures of pain, fatigue and appetite. In earlier clinical studies in advanced cancer patients, XBiotech discovered that subjects with preserved muscle mass and stabilization or improvement of these symptoms, had dramatically improved overall survival. The Company previously validated this endpoint in a phase III study in colorectal cancer patients and will explore this endpoint now with its new drug in pancreatic cancer.
The current study will commence with a Phase 1 portion to establish safety, tolerability and dosing of XB2001 in combination with ONIVYDE+5-FU/LV. The Phase I portion will serve to establish a recommended Phase 2 dose, which will involve enrollment of 60 patients randomized to receive either placebo+ONIVYDE+5-FU/LV or XB2001+ONIVYDE+5-FU/LV for up to 12 cycles.
Dr. Carl Gray, Principal Investigator at Community Cancer Trials of Utah, site of first patient enrollment, commented, “Pancreatic cancer remains an aggressive and difficult form of cancer to treat. If we can use XB2001 to improve outcomes and increase the tolerability of chemotherapy, this would be an exciting advance.”
John Simard, chairman and CEO of XBiotech stated, “Chemotherapy and paraneoplastic-related acute and chronic inflammatory responses play a key role in tumor progression and is a cause of significant morbidity with chemotherapy. Currently there is no approved therapy to specifically target this fundamental aspect of tumor biology or these effects of chemotherapy.”
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. XBiotech is undertaking discovery and clinical development programs across multiple disease areas. XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech is also leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Beter Bed Holding announces the issue of 946,167 new ordinary shares23.7.2021 18:00:00 CEST | Press release
Beter Bed Holding N.V. (“BBH” ISIN NL0000339703), the Netherlands’ leading sleep specialist in retail, wholesale and B2B, announces the issue of 946,167 new ordinary shares of the Company against an issue price of € 6.82. The issue of shares is meant to remediate the impact on the Company’s solvency from the repayment of the perpetual loan, as announced in the interim results press release dated 21 July 2021. The net proceeds of the Offering will be used to strengthen our financial position and to provide the Company with the financial flexibility to accelerate the execution of its growth strategy 2025 as presented during the AGM of 12 May 2021. The increased attention for health and well-being, due to COVID-19, is expected to lead to increased demand for quality sleep as one of the three pillars of health. The investment program driven by our strategy is starting through the launch of a new shop format, subscription label Leazzzy, investments in data analytics and acceleration of onli
Arcadis reports transactions under its current share buyback program23.7.2021 12:00:00 CEST | Press release
Amsterdam, July 23, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 91.282 of its own shares in the period from 16 July up to and including 22 July 2021 at an average price of €34.59. The consideration of this repurchase was €3.2 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.0 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: email@example.com ABOUT ARCADIS Arcadis is the leading global desig
Vaisala Corporation Half Year Financial Report January–June 202123.7.2021 08:00:00 CEST | Press release
Vaisala Corporation Half Year Financial Report July 23, 2021 at 9.00 a.m. (EEST) Vaisala Corporation Half Year Financial Report January–June2021 Excellent growth continued in second quarter Secondquarter 2021 highlights Orders received EUR 120.1 (95.9) million, increase 25%Order book at the end of the period EUR 165.3 (145.3) million, increase 14%Net sales EUR 109.5 (91.4) million, increase 20%Operating result (EBIT) EUR 10.9 (7.9) million, 10.0 (8.7) % 0f net salesEarnings per share EUR 0.25 (0.16)Cash flow from operating activities EUR 11.1 (-1.1) million January–June 2021 highlights Orders received EUR 226.3 (185.6) million, increase 22%Net sales EUR 201.5 (178.6) million, increase 13%Operating result (EBIT) EUR 19.0 (13.1) million, 9.5 (7.3) % 0f net salesEarnings per share EUR 0.43 (0.27)Cash flow from operating activities EUR 29.4 (4.2) million Market development and businessoutlook for 2021 Market for high-end industrial instruments is expected to continue growth after strong re
FLOW TRADERS Q221 RESULTS23.7.2021 07:30:00 CEST | Press release
FLOW TRADERS Q221 RESULTS Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q221 results and 2021 Half Year report. Highlights Market ETP Value Traded decreased 14% quarter-on-quarter and decreased 14% H121 vs H120Flow Traders ETP Value Traded decreased 15% quarter-on-quarter and decreased 6% H121 vs H120Flow Traders recorded NTI of €94.4m in Q221 reflecting a more normalised market environment. This compares to NTI of €142.2m in Q121 and €229.9m in Q220. H121 NTI was €236.6m vs €724.8m in H120Total operating expenses of €54.1m incurred in Q221 which includes €0.6m of one-off COVID-19 and business continuity plan-related expenses577 FTEs as at 30 June 2021 compared to 566 FTEs as at 31 March 2021Q221 EBITDA reached €40.3m with a margin of 43% contributing to H121 EBITDA of €119.6m with a margin of 51%Q221 Net Profit amounted to €28.7m with basic EPS of €0.66. H121 Net Profit amounted to €90.2m with basic EPS of €2.05IFR/IFD came into force on 26 Ju
Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million23.7.2021 07:00:00 CEST | Press release
Press Release July 23, 2021 Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million Second quarter 20211 Signify's installed base of connected light points increased from 83 million in Q1 21 to 862 million in Q2 21 Sales of EUR 1,609 million; 9.6% nominal sales growth and CSG of 14.1%LED-based sales represented 82% of total sales (Q2 2020: 80%)Adj. EBITA margin improved by 190 bps to 10.9%Net income increased to EUR 82 million (Q2 20: EUR 81 million)Free cash flow of EUR 104 million (Q2 20: EUR 158 million)Net debt/EBITDA ratio of 1.7x (Q2 20: 2.4x) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s second quarter 2021 results. “In the second quarter we saw an acceleration of the pace of recovery in comparison to the first three months of the year. We successfully executed our strategy as demand for our connected lighting offers and our growth pla
Norsk Hydro: Andre kvartal 2021 – Rekordresultater og fortsatt positivt markedssentiment23.7.2021 07:00:00 CEST | Pressemelding
Norsk Hydro ASA rapporterte en justert EBITDA på 6.598 millioner kroner i andre kvartal 2021, en økning fra 2,794 millioner kroner i samme kvartal i fjor. Fortsatt oppgang i verdensøkonomien bidrar til økt etterspørsel etter aluminium og aluminiumprodukter. Forretningsområdene Hydro Aluminium Metal og Hydro Extrusions rapporterte rekordresultater for kvartalet. Rekordresultat i Aluminium Metal på grunnlag av økte priser og produktpremier på LMERobust drift, forbedringsprogrammet foran skjema Sterke prestasjoner i Extrusions og framdrift i vekstprosjekterStyrking av bærekraftposisjon med investeringer for vekst i resirkuleringSalget av forretningsområdet Hydro Rolling til KPS Capital Partners fullført Høyere all-in metallpriser og volumer i Aluminium Metal, bedre marginer og volumer i Extrusions og bedre resultater fra Hydro Energy bidro positivt til justert EBITDA. Disse positive elementene ble delvis utliknet av høyere råvarekostnader oppstrøms og negative valutaeffekter. Den globale
Norsk Hydro: Second quarter 2021 - Record results and continued positive market sentiment23.7.2021 07:00:00 CEST | Press release
Norsk Hydro ASA posted second-quarter 2021 adjusted EBITDA of NOK 6,598 million, up from NOK 2,794 million in the same quarter last year. Continued global economic recovery is supporting increased demand for aluminium and aluminium products. Hydro Aluminium Metal and Hydro Extrusions business areas reported record quarterly results. Record result in Aluminium Metal supported by LME prices and premiumsRobust operations, improvement program ahead of plan Strong performance in Extrusions and progress on growth initiativesStrengthening sustainability position with growth investments in recyclingSale of Hydro Rolling business area to KPS Capital Partners completed Higher all-in metal prices and volumes in Aluminium Metal, improved margins and volumes in Extrusions, and better results from Hydro Energy contributed positively to adjusted EBITDA. These positive elements were partly offset by higher raw material costs upstream and negative currency effects. The second quarter saw a continuation